Initiation of dosing in our Phase 1b clinical trial represents an important step in the clinical development of GT-02287 and in Gain’s mission to deliver a disease-modifying therapy to people with ...

Interim Analysis Expected End of 2Q 2025 BETHESDA, MD / ACCESS Newswire / March 14, 2025 / Gain Therapeutics, Inc. (Nasdaq:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company lead ...

Gain Therapeutics (GANX) announced the dosing of the first participant with Parkinson’s disease in its Phase 1b clinical trial of GT-02287, the ...

The research findings primarily focus on individuals with a sleep disorder but may have broader implications. A recent study ...

A new study from McGill University has revealed that a blood test originally developed for Alzheimer's disease could predict ...

Idiopathic REM sleep behaviour disorder (iRBD) causes people to physically act out their dreams while sleeping. The disorder is also associated with a very high risk of Parkinson's disease and a ...

Stay informed with Hindustan Times' live updates! Track the latest lifestyle news including fashion trends, style guide & ...

For people with a certain sleep disorder, a simple blood test could help predict the development of dementia years before symptoms appear, a new study indicates. Idiopathic REM sleep behavior disorder ...

Teleneurorehabilitation provides similar improvement in motor and nonmotor symptoms for patients with Parkinson’s disease as ...

Researchers at McGill University found that a blood test originally designed for Alzheimer’s can predict dementia risk in ...